共 33 条
[1]
Cuisset T(2017)Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study Eur Heart J 38 3070-8
[2]
Deharo P(2011)Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding Academic Research Consortium[J] Circulation 123 2736-47
[3]
Quilici J(2009)Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J] N Engl J Med 361 1045-57
[4]
Mehran R(2019)Ticagrelor with or without aspirin in high-risk patients after PCI[J] N Engl J Med 381 2032-42
[5]
Rao SV(2016)2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J] J Thorac Cardiovasc Surg 152 1243-75
[6]
Bhatt DL(2019)Premature Ticagrelor discontinuation in secondary Prevention of atherosclerotic CVD: JACC Review topic of the Week[J] J Am Coll Cardiol 73 2454-64
[7]
Wallentin L(2017)EUCLID Trial Steering Committee and investigators. Ticagrelor versus Clopidogrel in Symptomatic Peripheral artery Disease[J] N Engl J Med 376 32-40
[8]
Becker RC(2018)Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial[J] Lancet 392 940-9
[9]
Budaj A(2016)Platelet inhibition with Ticagrelor 60 mg Versus 90 mg twice daily in the PEGASUS-TIMI 54 trial.[J] J Am Coll Cardiol 67 1145-54
[10]
Mehran R(2018)Effect of low-dose Versus Standard-Dose Ticagrelor and Clopidogrel on platelet inhibition in Acute Coronary Syndromes[J] J Am Coll Cardiol 71 1594-75